Waters has the reach and scale to leverage Wyatt’s successful legacy and extend the benefits of our offerings to many new applications and customers. Becoming an integral part of Waters is a natural way for us to expand our business dramatically. “For decades, we have seen firsthand how closely Waters and Wyatt’s scientific heritage, ethos, and values have been aligned. Philip Wyatt, Chairman and Founder of Wyatt Technology. “For more than 40 years, our company has delighted its customers using the unique products and unparalleled personal service we deliver to support life-enhancing large molecule therapeutics,” said Dr. We look forward to welcoming the Wyatt team to the Waters family.” We share a common mission to harness our technology and deep scientific expertise to increase the availability and affordability of life-changing therapies. “While biologics therapies, including cell and gene therapies, can dramatically change the quality of life for a significant percentage of the population, the cost of delivering these therapies is a major barrier for broader adoption. Udit Batra, President and CEO, Waters Corporation. Now we are entering the next phase of our strategy to accelerate value creation and generate faster growth,” said Dr. “Over the past two years, Waters has regained our commercial momentum, revitalized innovation and put an outstanding leadership team in place. Together, its innovative product offerings are used across the value chain in discovery, product development, manufacturing, and QA/QC settings to determine the critical quality attributes of novel therapeutics such as cell and gene therapies, vaccines, and proteins, as well as synthetic polymers and nanoparticles. Over the years, Wyatt has added several complementary technologies, including well-plate based dynamic light scattering and field-flow fractionation for separating nanoparticles in solution. Since Wyatt's scientists were the first to commercialize on-line multi-angle laser light scattering instruments more than 40 years ago, Wyatt has been defining and redefining state-of-the-art macromolecular characterization instrumentation, software, and services to solve its customers’ unmet needs. With a worldwide workforce of more than 200 employees, Wyatt has been delivering world-class training and personal service to a global base of scientific customers. By applying Waters’ well-established business model, Empower informatics software, global reach and scale, Waters and Wyatt are well-positioned to build a high-growth bioanalytical characterization business.īased in Santa Barbara, Calif., Wyatt is a privately held family company with 2022 revenues of approximately $110 million. The transaction is expected to close in the second quarter of 2023, subject to regulatory approvals and other customary closing conditions.īioanalytical characterization for new modalities including cell and gene therapies is a significant market opportunity, with a $1.8 billion total addressable market and 10-12% projected annual growth i. Waters Corporation (NYSE:WAT) today announced it has entered into an agreement to acquire Wyatt Technology, a pioneer in innovative light scattering and field-flow fractionation instruments, software, accessories, and services, for $1.36 billion in cash, subject to certain adjustments.
#Dynamic light scattering instrument cost plus
Transaction is immediately accretive to revenue growth and margin profile, with adjusted EPS accretion beginning in Q1 2024 and high single-digit plus ROIC by year five.
#Dynamic light scattering instrument cost software
Wyatt is a rapidly growing leader in light scattering technology and advanced software solutions with significant exposure to bioanalytical characterization including cell and gene therapies. Accelerates next phase of Waters’ strategy for growth and value creation through increased exposure in attractive, high-growth adjacent markets.
0 kommentar(er)
